Fostiva

Top-line data is expected from two of Ophthotech Corp (NASDAQ: OPHT)'s pivotal Phase III trials in the next month. Leading into the catalyst, which could take the stock either way, Stifel analyst Stephen Willey maintains a Buy rating and $75 price target on the stock, representing about 135 upside...